NCT02843035View on ClinicalTrials.gov

Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 4, 2017

Primary Completion Date

October 30, 2026

Study Completion Date

October 30, 2026

Conditions
Gaucher Disease Type 1Gaucher Disease Type 3
Interventions
DRUG

venglustat (GZ402671)

"Pharmaceutical form: capsule or tablet~Route of administration: oral"

DRUG

imiglucerase

"Pharmaceutical form: sterile lyophilized product~Route of administration: intravenous"

Trial Locations (7)

22030

Lysosomal and Rare Disorders Research and Treatment Center, Inc Site Number : 840003, Fairfax

55131

Investigational Site Number : 276001, Mainz

75226

Baylor Institute of Metabolic Diseases Site Number : 840001, Dallas

06520

Yale University School of Medicine Site Number : 840002, New Haven

105-8471

Investigational Site Number : 392001, Minato-ku

CB2 OQQ

Investigational Site Number : 826003, Cambridge

M6 8HD

Investigational Site Number : 826002, Salford

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY